New glucose‐lowering therapies like DPP‐4 inhibitors, GLP‐1 receptor agonists, and SGLT‐2 inhibitors have undergone cardiovascular outcome trials (CVOTs) for type 2 diabetes (T2DM), as by the guidance of the FDA. Here, SLC5A2 is linked to type 2 diabetes mellitus.